刘娟,颜红兵,宋莉,华倚虹,赵汉军,刘臣,周鹏,李建楠,谭宇

• 1:北京协和医学院中国医学科学院阜外医院心内科国家心血管病中心心血管疾病国家重点实验室

摘要(Abstract)：

目的分析稳定性冠心病患者应用替格瑞洛12个月的依从性、影响因素和对预后的影响。方法连续收集阜外医院2015年1月1日至6月30日住院期间和出院后继续服用替格瑞洛的稳定性冠心病患者,通过病历查阅、电话或门诊获得患者长期用药资料,并在出院后6个月和12个月进行随访。结果本研究共纳入155例高危稳定性冠心病患者(104例接受介入治疗),其中男性122例(78.7%),平均年龄(57.0±10.0)岁,既往心肌梗死50例(32.3%),左主干或多支病变106例(68.4%)。出院12个月内46例(29.7%)患者提前停服替格瑞洛,其中25例(54.3%)替换为氯吡格雷。发生出血事件和当地无药是提前停服替格瑞洛的主要原因。单因素分析显示,年龄、体重指数、高血压病和当地是否有药与提前停服替格瑞洛相关。多因素分析显示,患者年龄越大(OR 4.13,95%CI 1.40~12.19,P=0.012),依从性越差,而当地有药物(OR 0.25,95%CI 0.09~0.69,P=0.013)患者依从性好。但提前停服替格瑞洛并不增加不良心血管事件(心源性死亡、卒中、心肌梗死)的发生率(P=0.761)。结论稳定性冠心病患者出院后服用替格瑞洛依从性较差,年龄大与当地无药是依从性差的独立预测因子。尽管停服替格瑞洛,但并没有增加不良心血管事件发生率。

关键词(KeyWords)： 替格瑞洛;稳定性冠心病;依从性

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘娟,颜红兵,宋莉,华倚虹,赵汉军,刘臣,周鹏,李建楠,谭宇

参考文献(References)：

• [1]Wallentin L,Becker R C,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [2]Bonaca M P,Bhatt D L,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med,2015,372(19):1791-1800.
• [3]Bonaca M P,Bhatt D L,Oude O T,et al.Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events:a secondary analysis of the PEGASUSTIMI 54 trial.JAMA Cardiol,2016,1(4):425-432.
• [4]刘娟,颜红兵,宋莉,等.急性冠状动脉综合征患者院外服用替格瑞洛现状调查分析.中华医学杂志,2017,97(15):1165-1169.
• [5]Montalescot G,Sechtem U,Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease:the task force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J,2013,34(38):2949-3003.
• [6]Udell JA,Bonaca MP,Collet JP,et al.Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction:a collaborative meta-analysis of randomized trials.Eur Heart J,2016,37(4):390-399.
• [7]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [8]Parodi G,Storey RF.Dyspnoea management in acute coronary syndrome patients treated with ticagrelor.Eur Heart J Acute Cardiovasc Care,2015,4(6):555-560.
• [9]Goto S,Huang CH,Park SJ,et al.Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study.Circ J,2015,79(11):2452-2460.
• [10]Kang HJ,Clare RM,Gao R,et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome:A retrospective analysis from the platelet inhibition and patient outcomes(PLATO)trial.Am Heart J,2015,169(6):899-905.
• [11]邵春丽,颜红兵,乔树宾,等.替格瑞洛相关呼吸困难的调查分析.中国介入心脏病学杂志,2015,23(2):85-88.
• [12]Bosworth HB,Granger BB,Mendys P,et al.Medication adherence:a call for action.Am Heart J,2011,162(3):412-424.
• [13]Garavalia L,Ho PM,Garavalia B,et al.Clinician-patient discord:exploring differences in perspectives for discontinuing clopidogrel.Eur J Cardiovasc Nurs,2011,10(1):50-55.
• [14]王绪云,席少枝,刘佳,等.冠心病患者替格瑞洛停药原因及停药对临床转归的影响分析.中华老年多器官疾病杂志,2016,15(3):231-236.
• [15]Kumbhani DJ,Fonarow GC,Cannon CP,et al.Predictors of adherence to performance measures in patients with acute myocardial infarction.Am J Med,2013,126(1):71-74.
• [16]Spertus JA,Kettelkamp R,Vance C,et al.Prevalence,predictors,and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement:results from the PREMIER registry.Circulation,2006,113(24):2803-2809.